Type I IFN receptor controls activated TYK2 in the nucleus: Implications for EAE therapy

Journal of Neuroimmunology

Volumn 254, Issue 1-2, 2013, Pages 101-109

  Ahmed, Chulbul M ^a   Noon Song, Ezra N ^a   Kemppainen, Kaisa ^a   Pascalli, Massimo P ^a   Johnson, Howard M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Histone modification; Interferon alpha; Interferon tau; Multiple sclerosis; Nuclear TYK2; Steroid like signaling

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA INTERFERON RECEPTOR 1; ALPHA INTERFERON RECEPTOR 2; ALPHA1 INTERFERON; BETA INTERFERON; HISTONE H3; INTERFERON; INTERFERON ALPHA1 (69-189); INTERFERON ALPHA1 (69-189)R9; INTERFERON BETA (100-179) R9; INTERFERON MIMETIC; INTERFERON RECEPTOR; LYSINE; N TERMINAL TRUNCATED TYPE 1 INTERFERON; N TERMINAL TRUNCATED TYPE 1 INTERFERON ALPHA1; N TERMINAL TRUNCATED TYPE 1 INTERFERON R9; PROTEIN KINASE TYK2; RECEPTOR SUBUNIT; STAT1 PROTEIN; STAT2 PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEMETHYLATION; ENZYME ACTIVATION; FEMALE; GENE; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OAS1 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; CULTURE MEDIA, SERUM-FREE; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME ACTIVATION; FEMALE; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; INTERFERON-ALPHA; MICE; MICE, INBRED STRAINS; PEPTIDES; RECEPTOR, INTERFERON ALPHA-BETA; STAT TRANSCRIPTION FACTORS; TIME FACTORS; TRANSFECTION; TYK2 KINASE;

EID: 84871707927     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.10.006     Document Type: Article

References (46)

1. Ahmed C.M., Johnson H.M. IFNγ and its receptor subunit IFNGR1 are recruited to the IFNγ-activated sequence element at the promoter site of IFNγ-activated genes: evidence of transactivational activity in IFNGR1. J. Immunol. 2006, 177:315-321.
2. Ahmed C.M., Wills K.N., Sugarman B.J., Johnson D., Ramachandra M., Nagabhushan T.L., Howe J.A. Selective expression of nonsecreted interferons by an adenoviral vector confers antiproliferative and antiviral properties and causes inhibition of tumor growth in nude mice. J. Interferon Cytokine Res. 2001, 21:399-408.
3. Ahmed C.M., Burkhart M.A., Mujtaba M.G., Subramaniam P.S., Johnson H.M. The role of IFNgamma nuclear localization sequence in intracellular function. J. Cell Sci. 2003, 116:3089-3098.
4. Ahmed C.M., Martin J.P., Johnson H.M. IFN gamma mimetic as a therapeutic for lethal vaccinia virus infection: possible effects on innate and adaptive immune responses. J. Immunol. 2007, 178:4576-4583.
5. Arnason B.G., Reder A.T. Interferons and multiple sclerosis. Clin. Neuropharmacol. 1994, 17:495-547.
6. Berger S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447:407-412.
7. Blalock J.E., Baron S. Mechanism of interferon induced transfer of viral resistance between animal cells. J. Gen. Virol. 1979, 42:367-372.
8. Brod S.A., Marshall G.D., Henninger E.M., Sriram S., Khan M., Wolinsky J.S. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996, 46:1633-1638.
9. Burks J. Interferon-beta1b for multiple sclerosis. Expert. Rev. Neurother. 2005, 5:153-164.
10. Castro-Borrero W., Graves D., Frohman T.C., Flores A.B., Hardeman P., Logan D., Orchard M., Greengerg M., Frohman E.M. Current and emerging therapies in multiple sclerosis: a systematic review. Ther. Adv. Neurol. Disord. 2012, 5:205-220.
11. Dawson M.A., Bannister A.J., Gottgens B., Foster S.D., Bartke T., Green A.R., Kouzarides T. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin. Nature 2009, 461:819-822.
12. Dayal A.S., Jensen M.A., Lledo A., Arnason B.G. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995, 45:2173-2177.
13. Duvallet E., Semerano L., Assier E., Falgarone G., Boissier M.C. Interleukin-23: a key cytokine in inflammatory diseases. Ann. Med. 2011, 43:503-511.
14. Ebers G.C. Natural history of primary progressive multiple sclerosis. Mult. Scler. 2004, 10(Suppl. 1):S8-S13. (discussion S-5).
15. Francis G.S., Grumser Y., Alteri E., Micaleff A., O'Brien F., Alsop J., Stam Moraga M., Kaplowitz N. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf. 2003, 26:815-827.
16. Giovannoni G., Southam E., Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult. Scler. 2012, 18:932-946.
17. Gough D.J., Levy D.E., Johnstone R.W., Clarke C.J. IFN gamma signaling-does it mean JAK-STAT?. Cytokine Growth Factor Rev. 2008, 19:383-394.
18. Jager L.D., Dabelic R., Waiboci L.W., Ahmed C.M., David S., Johnson H.M. The kinase inhibitory region of SOCS-1 is sufficient to inhibit T helper 17 function in experimental allergic encephalomyelitis. J. Neuroimmunol. 2011, 232:108-118.
19. Johnson H.M., Ahmed C.M. Gamma interferon signaling: insights to development of interferon mimetics. Cell. Mol. Biol. 2006, 52:71-76.
20. Johnson H.M., Subramaniam P.S., Olsnes S., Jans D.A. Trafficking and signaling pathways of nuclear localizing protein ligands and their receptors. BioEssays 2004, 26:993-1004.
21. Johnson H.M., Noon-Song E.N., Kemppainen K., Ahmed C.M. Steroid-like signaling by interferons: making sense of specific gene activation by cytokines. Biochem. J. 2012, 443:329-338.
22. Jones L., Vignali D.A. Molecular interactions within IL-6/IL-12 cytokine/receptor superfamily. Immunol. Res. 2011, 51:5-14.
23. Kieseier B.C. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 2011, 25:491-502.
24. Kushnaryov V.M., MacDonald H.S., Deburin J., Lemense G.P., Sedmark J.J., Grossberg S.E. Internalization and transport of mouse beta-interferon into the cell nucleus. J. Interferon Res. 1986, 6:241-245.
25. Levy D.E., Darnell J.E. STATs: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
26. Lobie P., Ronsin B., Silvennoinen O., Haldosen L.A., Norstedt G., Morel G. Constitutive nuclear localization of Janus kinases 1 and 2. Endocrinology 1996, 137:4037-4045.
27. Mehta N.T., Truax A.D., Boyd N.H., Greer S.F. Early epigenetic events regulate the adaptive immune response gene CIITA. Epigenetics 2011, 6:16-25.
28. Nilsson J., Bjursell G., Kannius-Janson M. Nuclear JAK2 and transcription factor NF1-C2: a novel mechanism of prolactin signaling in mammary epithelial cells. Mol. Cell. Biol. 2006, 26:5663-5674.
29. Noon-Song E.N., Ahmed C.M., Dabelic R., Canton J., Johnson H.M. Controlling nuclear JAKs and STATs for specific gene activation by IFNγ. Biochem. Biophys. Res. Commun. 2011, 410:648-653.
30. Ragimbeau J., Dondi E., Vasserot A., Romero P., Uze G., Pellegrini S. The receptor interaction region of TYK2 contains a motif for its nuclear localization. J. Biol. Chem. 2001, 276:30812-30818.
31. Rutherford M.N., Kumar A., Coulombe B., Skup D., Carver D.H., Williams B.R. Expression of intracellular interferon constitutively activates ISGF3 and confers resistance to EMC viral infection. J. Interferon Cytokine Res. 1996, 16:507-510.
32. Schwid S.R., Thorpe J., Sharief M., Sandberg-Wollheim M., Rammohan K., Wendt J., Panitch H., Goodin D., Li D., Chang P., Francis G. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch. Neurol. 2005, 62:785-792.
33. Stanisic V., Lonard D.M., O'Malley B.W. Modulation of steroid hormone receptor activity. Prog. Brain Res. 2010, 181:153-176.
34. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., Schreiber R.D. How cells respond to interferon. Ann. Rev. Biochem. 1998, 67:227-264.
35. Subramaniam P.S., Johnson H.M. The IFNRA1 subunit of the type I IFN receptor complex contains a functional nuclear localization sequence. FEBS Lett. 2004, 578:207-210.
36. Subramaniam P.S., Khan S.A., Pontzer C.H., Johnson H.M. Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:12270-12274.
37. Szente B.E., Subramaniam P.S., Johnson H.M. Identification of IFNgamma receptor binding sites for JAK2 and enhancement of binding by IFN-gamma and its C-terminal peptide IFN-gamma(95-133). J. Immunol. 1995, 155:5617-5622.
38. Szente B.E., Weiner I.J., Jablonsky M.J., Krishna N.R., Torres B.A., Johnson H.M. Structural requirements for agonist activity of a murine interferon-gamma as assessed by monoclonal antibodies. J. Interferon Cytokine Res. 1996, 16:813-817.
39. Takoka A., Mitani Y., Suemori H., Sato M., Yokochi T., Noguchi S., Tanaka N., Taniguchi T. Cross talk between interferon gamma and alpha/beta signaling components in caveolar membrane domains. Science 2000, 288:2357-2360.
40. Taniguchi T., Takaoka A. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci. 2008, 7:1-8.
41. Thomas C., Moraga I., Levin D., Krutzik P.O., Podoplelova Y., Trejo A., Lee C., Yarde G., Vleck S.E., Glenn J.S., Nolan G.P., Piehler J., Schreiber G., Garcia K.C. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011, 146:621-632.
42. Trapp B.D., Nave K.-A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
43. Wang Y., Hung M.C. Nuclear functions and subcellular trafficking mechanisms of epidermal growth factor receptor family. Cell Biosci. 2012, 2:13.
44. Wang Y., Yamaguchi H., Huo L., et al. The translocon sec61β localized in the inner nuclear membrane transports membrane-embedded EGF receptor to nucleus. J. Biol. Chem. 2010, 285:38720-38729.
45. Yang X.P., Ghoreschi K., Steward-Tharp S.M., Rodriguez-Canales J., Grainger J.R., Hirahara K., Sun H.W., Wei L., Vahedi G., Kanno Y., O'Shea J.J., Laurence A. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 2011, 12:247-254.
46. Zouein F.A., Duhe R.J., Booz G.W. JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. Growth Factors 2011, 29:245-252.